Lv3
360 积分 2024-10-16 加入
Targeted Therapies for Lung Cancer Patients With Oncogenic Driver Molecular Alterations
2天前
已完结
Befotertinib (D-0316) versus icotinib as first-line therapy for patients with EGFR-mutated locally advanced or metastatic non-small-cell lung cancer: a multicentre, open-label, randomised phase 3 study
12天前
已完结
Individualised neoantigen therapy mRNA-4157 (V940) plus pembrolizumab versus pembrolizumab monotherapy in resected melanoma (KEYNOTE-942): a randomised, phase 2b study
13天前
已完结
A brief review of RNA modification related database resources
17天前
已完结
Brief report: Ivonescimab combined with etoposide plus carboplatin as first-line treatment for extensive-stage small-cell lung cancer: results of a phase Ib clinical trial
27天前
已完结
CAR T cell therapy for patients with solid tumours: key lessons to learn and unlearn
1个月前
已完结
Use of Immunotherapy With Programmed Cell Death 1 vs Programmed Cell Death Ligand 1 Inhibitors in Patients With Cancer
1个月前
已完结
A risk-management approach for effective integration of biomarkers in clinical trials: perspectives of an NCI, NCRI, and EORTC working group
1个月前
已完结
Current insights into protein solubility: A review of its importance for alternative proteins
1个月前
已完结
[Expert consensus on immunotherapy for small cell lung cancer (2025 edition)]
1个月前
已完结
皖公网安备34019202002308
